Hers vs Ivim Health: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Ivim Health beats Hers overall, scoring 7.9/10 vs 7.3/10. Ivim Health is more affordable at $150/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Ivim Health for users who want personalized dosing with frequent provider ch.

A side-by-side comparison of Hers and Ivim Health covering pricing, scores, medication types, insurance, and more to help you decide.

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

Ivim Health

#11 of 48

7.9/10

Personalized GLP-1 program with frequent provider check-ins and customized dosing schedules at an affordable price point.

Visit Ivim Health

Feature	Hers	Ivim Health
Our Score	7.3/10	7.9/10
Starting Price	$199/mo	$150/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Users who want personalized dosing with frequent provider check-ins
Ranking	#35	#11

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Ivim Health

Pros

+$75/mo starting price is among the lowest in the market for a program with actual provider oversight
+Bi-weekly provider check-ins included — more frequent than most platforms at this price point
+Personalized titration schedules based on individual tolerance, not cookie-cutter dose escalation
+Both brand-name and compounded available, with the option to switch based on response

Cons

−The $75/mo starting price increases with dose — expect $150-200/mo at maintenance doses
−No insurance billing, and the cost increase at higher doses isn't always clearly communicated upfront

Our Verdict

Ivim Health edges out Hers with a score of 7.9/10 vs 7.3/10. If budget is your priority, Ivim Health starts at $150/mo compared to Hers's $199/mo. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Ivim Health if you want: users who want personalized dosing with frequent provider check-ins.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hers nor Ivim Health feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review